30 Sep 2015 10:30
Tiziana Life Sciences has been granted an exclusive license to develop and commercialise Novimmune SA's CD3 receptor monoclonal antibody foralumab. Foralumab can be utilised for a range of autoimmune and inflammatory diseases, such multiple sclerosis, type-1 diabetes, inflammatory bowel disease, pso
Read more